Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Good question. Personally I think the whole Moonshot thing is a pile of balls. And while ODX have the quality test which will sell , I am not relying on the clowns in government to buy it.
You can see in this tweet who the government are proposing for lateral test. It’s not ODX, NCYT, AVCT. It’s Optigene. https://twitter.com/carolecadwalla/status/1303953046230241281?s=21
“ The Health Service Journal reported that Ben Davison, an NHS Digital director, had told a board meeting there was a “strategy to scale up to 10 million tests per day”.
The ambition is likely to reflect a desire for more widespread community testing, rather than a programme that relies on people coming forward with symptoms.“ Sounds like antibodies.
Said today. Wouldn’t it be great to be invested in a company that has blogged this last week - We are excited to bring to the table a variety of products from our respiratory testing panel to our qPCR multiplex assay that can diagnose patients from one test with Influenza, RSV or COVID-19 in one test.
Oh hold on ...
Yes Bloomberg report on finger prick test which Imperial used is more muted: "There was no breakthrough on the quest for a home antibody test for general use among the public. Separate studies, also unveiled on Thursday, evaluated a range of finger-prick home antibody tests but found the results were not reliable enough to be given government approval for widespread use, officials said. The tests were still deemed to be suitable for surveillance studies such as the Imperial research"
They are very strict about confidentiality with such large tendering exercises. Any leaks would be dangerous as it could detrimentally affect fair competition. Usually the buyer would agree in principle and then there would be due diligence re indicators, Service Level Agreements etc within a 2 week period. If the Telegraph reports it first I would be worried as this may mean the award could be challenged. Communication of awards is set out in European Regs. PHE will tell the suppliers before they update TED. Then provided the contract is completed the supplier update the market.
Screenshot https://ibb.co/1drmbsm
With the best will in the world it cannot be approved without a larger scale trial. And I am Team SNG. It would not be ethical to fast track regulation without larger numbers. However the will is there and I can see the NHS and international health authorities assisting with recruitment.
No this is an old result! We are waiting on this https://ted.europa.eu/udl?uri=TED%3ANOTICE%3A263375-2020%3ATEXT%3AEN%3AHTML&fbclid=IwAR0wjM8zLSLkRnK5uml7bqgMkpMFqIVxZQ1MR0YvTrDJbJIM4d0fBmldJGg
Finding it quite infuriating when people complain about lack of PR etc. I assume they are well placed to apply for a portion of this £5bn contract. I get my work through public procurement, you are not allowed to tell anyone that you are bidding. If you did, you could be accused of collusion. Even after you have put your bid in you can’t talk about it during the decision making period. So NCYT have to keep schtum about everything.
It is a bit misleading to add the caveat that it hasn’t been peer reviewed IMO. Listed companies have to release price sensitive information. Peer reviews come many months later. There are checks and balances built in, with an independent investigator. You don’t need a peer review to get approval. Yes, they can be persuasive but the real issues for the FDA or similar is proven efficacy and safety. Safety we can tick off. Efficacy - will need larger scale however the will is there, this will not be drawn out as there are fast track processes.
Yes I am delighted for them. They are a touch of class, and have had a tough time with Woodford and AZN giving the license back, I wonder how they are feeling now? I have been burnt badly with pharma before so have only just bought in. The different outcomes in the treatment compared to placebo are remarkable, there’s little room for doubt on efficacy. Plus I see that improvement was not as significant for patients with more severe disease at the time of admission. This bodes well for the home trials. Well done you brave holders.